117 related articles for article (PubMed ID: 16216433)
1. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Takeuchi M
Med Hypotheses; 2006; 66(2):273-5. PubMed ID: 16216433
[TBL] [Abstract][Full Text] [Related]
2. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
3. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
Yamagishi S; Matsui T; Nakamura K; Takeuchi M
Int J Tissue React; 2005; 27(4):189-95. PubMed ID: 16440584
[TBL] [Abstract][Full Text] [Related]
4. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
5. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
6. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
7. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
9. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression.
Li L; Renier G
Metabolism; 2006 Nov; 55(11):1516-23. PubMed ID: 17046555
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
12. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Yamagishi S; Matsui T; Nakamura K
Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein kinase C might be harmful to diabetic retinopathy.
Yamagishi S; Takeuchi M
Med Hypotheses; 2004; 63(1):135-7. PubMed ID: 15193366
[TBL] [Abstract][Full Text] [Related]
15. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Okuda S; Imaizumi T
Ophthalmic Res; 2008; 40(1):10-5. PubMed ID: 18025836
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
18. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
[TBL] [Abstract][Full Text] [Related]
20. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
Yamagishi S; Abe R; Inagaki Y; Nakamura K; Sugawara H; Inokuma D; Nakamura H; Shimizu T; Takeuchi M; Yoshimura A; Bucala R; Shimizu H; Imaizumi T
Am J Pathol; 2004 Dec; 165(6):1865-74. PubMed ID: 15579431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
